A Phase 1/2 interventional study of Venetoclax and Cyclophosphamide in Lymphoma, Non-Hodgkin, sponsored by Hoffmann-La Roche. Completed at 52 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-11.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, 1 of them phase 3. venetoclax · Lymphoma, Non-Hodgkin.
Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, this one is the 2nd largest by enrollment, is one of 3 that started in 2013, is one of 5 in phase 1/2, and was the 7th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Melbourne Health · Sites in Australia
Ages 18–75
AbbVie · Sites in United States, Australia
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 6 · Phase 3 2
First in 2011; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 25 across the 23 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 23 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2013, is one of 13 in phase 1/2, and was the 32nd registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
3 of the studies testing venetoclax in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03844048Phase 3AbbVieAn Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | 2027-08 |
| NCT05053659Paolo Caimi, MDLoncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | 2026-11 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone (CHOP) in participants with Non-Hodgkin's Lymphoma (NHL). The study consisted of 2 stages: a dose-finding Phase Ib stage and a Phase II expansion stage. In the Phase I portion of the study, participants were randomized to one of 2 treatment arms venetoclax in combination with R-CHOP (Arm A) and venetoclax in combination with G-CHOP (Arm B) and explored the doses of venetoclax in combination with R-CHOP and G-CHOP. The maximum tolerated dose (MTD) of venetoclax in combination with R-CHOP and G-CHOP was determined during the dose-finding stage. For the Phase II portion of the study, the venetoclax dose for venetoclax + R-CHOP was on a non-continuous dosing schedule as determined by the Phase Ib portion of the study based on safety and tolerability observed in participants treated in the dose escalation portion of the study. On 17 July 2016, Roche/Genentech as the sponsor of Study BO21005 (Goya study), a Phase III study that evaluated G CHOP versus R-CHOP in 1L DLBCL, informed through a press release that the primary endpoint of investigator-assessed PFS was not met. Given these results, Arm B (venetoclax + G-CHOP) was not expanded in Phase II in patients who are first-line with DLBCL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General Inclusion Criteria:
Dose-Escalation Portion of the Study:
Expansion Portion of the Study:
Exclusion Criteria:
General Exclusion Criteria:
Dose-Escalation Portion of the Study:
Expansion Portion of the Study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
Drug: Venetoclax · Drug: Cyclophosphamide · Drug: Obinutuzumab · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
Drug: Venetoclax · Drug: Cyclophosphamide · Drug: Rituximab · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4-10 of Cycle 1 and Days 1-10 of Cycles 2-8 during Phase I and MTD will be administered according to the same schedule during Phase II.
Also known as: GDC-0199, ABT-199
Cyclophosphamide 750 milligrams per square meter (mg/m\^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
Rituximab 375 mg/m\^2 dose will be administered IV on Day 1 of every 21-day cycle.
Also known as: MabThera/Rituxan
Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Vincristine 1.4 mg/m\^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)
DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade \>/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs.
Time frame: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)
Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy
Time frame: Baseline up to end of treatment (up to approximately 6 months)
Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
Time frame: Baseline up to end of treatment (up to approximately 6 months)
Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)
AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as hour\*micrograms per milliliter (hr\*mcg/mL)
Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)
Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)
Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.
Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)
Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as micrograms per milliliter
Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval
Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.
Time frame: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)
Prednisone Plasma PK: AUC
AUC was determined based on measurement of Predisone concentrations in plasma over time.
Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
Prednisone Plasma PK: Tmax
Tmax was determined based on measurement of Predisone concentrations in plasma over time.
Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
Prednisone Plasma PK: Cmax
Cmax was determined based on measurement of Predisone concentrations in plasma over time.
Time frame: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)
Rituximab PK: Cmax
Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.
Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Rituximab PK: Cmin Within the Dosing Interval
Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2.
Time frame: Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)
Obinutuzumab PK: Cmax
Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.
Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Cyclophosphamide PK: Cmax
Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1.
Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Doxorubicin PK: Cmax
Cmax was determined using the post-dose Doxorubicin plasma concentrations.
Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Vincristine PK: Cmax
Cmax was determined using the post-dose Vincristine plasma concentrations.
Time frame: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)
Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC
Objective Response defined as PR (partial response) or CR (complete response) at end of treatment. CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR
Time frame: Baseline to end of treatment (up to approximately 6 months)
Percentage of Participants Who Are Alive and Without Disease Progression at Month 12
Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: \>/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions.
Time frame: Month 12
Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification
CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to \</= 1.5 cm in longest transverse diameter of a lesion (LDi), no extra-lymphatic sites of disease, absence of non-measured lesions, organ enlargement must have regressed to normal, no new lesions, and if the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
Time frame: Baseline up to end of treatment (approx. 6 months)
Safety: Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline up to approximately 36 months
Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy
Maintenance of relative dose intensity was defined as a dose intensity of \>/= 90%.
Time frame: Baseline up to Cycle 6 (cycle length = 21 days)
Relative Dose Intensity of Venetoclax
Dose intensity was categorized as \< 80%, 80% to \< 85%, 85% to \< 90%, or \>/= 90%.
Time frame: Baseline up to Cycle 6 (cycle length = 21 days)
At start the trial had a randomised-controlled component, until July 2016 once the arm B (Gazyva) got closed following the publication of results of another trial. Since July 2016, the trial was single-arm, not randomised anymore, and kept including patients in only 1 arm (Arm A, rituximab).
| Milestone | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 3 | 8 | 6 | 0 | 7 | 7 | 6 | 6 | 6 |
| Completed | 6 | 3 | 7 | 3 | 0 | 5 | 5 | 6 | 6 | 6 |
| Not completed | 1 | 0 | 1 | 3 | 0 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 208 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 159 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 49 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 33 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 |
DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade \>/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs.
| Participants | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax 800mg + R-CHOP | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg + G-CHOP B |
|---|---|---|---|---|---|---|---|---|---|
| Safety: Number of Participants With Dose-Limiting Toxicities (DLTs) | 1 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy
| Percentage of participants | Venetoclax + R-CHOP 800 mg Phase II |
|---|---|
| Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC) | 68.2 (61.50 to 74.47) |
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
| Percentage of participants | Venetoclax + R-CHOP 800 mg Phase II |
|---|---|
| Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC | 66.7 (55.32 to 76.76) |
AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as hour\*micrograms per milliliter (hr\*mcg/mL)
| hr*mcg/mL | Venetoclax 800mg + R-CHOP | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax + R-CHOP 800 mg | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax + G-CHOP 800mg |
|---|---|---|---|---|---|---|---|---|---|
| Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC) | .66 ± NA | 2.51 ± .97 | 3.87 ± 2.41 | 3.70 ± 1.59 | 4.51 ± 2.32 | 2.55 ± 1.13 | 4.33 ± 1.31 | 5.13 ± 2.41 | 6.20 ± 1.71 |
Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.
| Hour | Venetoclax + R-CHOP 100 mg | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax 800mg + R-CHOP | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax + G-CHOP 800 mg |
|---|---|---|---|---|---|---|---|---|---|
| Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax) | 4.0 ± NA | 4.59 ± 1.08 | 6.50 ± 1.91 | 5.52 ± 2.07 | 5.53 ± 1.55 | 5.72 ± 1.42 | 6.56 ± 1.51 | 5.30 ± 2.38 | 5.79 ± 1.47 |
Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as micrograms per milliliter
| Ug/ML | Venetoclax + R-CHOP 100 mg | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax 800mg + R-CHOP | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax + G-CHOP 800 mg |
|---|---|---|---|---|---|---|---|---|---|
| Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax) | .09 ± NA | .58 ± .32 | .92 ± .64 | .85 ± .33 | 1.15 ± .48 | .52 ± .21 | 1.26 ± .30 | 1.00 ± .58 | 1.54 ± .37 |
Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.
| mcg/mL | Venetoclax + R-CHOP 100 mg | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax 800mg + R-CHOP | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax + G-CHOP 800 mg |
|---|---|---|---|---|---|---|---|---|---|
| Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval | 0.0714 ± 0.00 | 0.522 ± 0.441 | 0.253 ± 0.247 | 0.387 ± 0.141 | 0.640 ± 0.451 | 0.134 ± 0.107 | 0.395 ± 0.381 | 0.612 ± 0.535 | 0.628 ± 0.395 |
AUC was determined based on measurement of Predisone concentrations in plasma over time.
| hr*mcg/mL | Venetoclax PK Popluation |
|---|---|
| Cycle 1, Day 1 | 195 ± 72.8 |
| Cycle 2, Day 1 | 184 ± 81.2 |
Tmax was determined based on measurement of Predisone concentrations in plasma over time.
| Hour | Venetoclax PK Popluation |
|---|---|
| Cycle 1, Day 1 | 2.19 ± 1.61 |
| Cycle 2, Day 1 | 3.80 ± 2.52 |
Cmax was determined based on measurement of Predisone concentrations in plasma over time.
| Ng/ML | Venetoclax PK Popluation |
|---|---|
| Cycle 1, Day 1 | 49.9 ± 28.7 |
| Cycle 2, Day 1 | 43.2 ± 17.6 |
Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.
| mcg/mL | Venetoclax 800 mg |
|---|---|
| Rituximab PK: Cmax | 173 ± 39.4 |
Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2.
| mcg/mL | Venetoclax 800 mg |
|---|---|
| Rituximab PK: Cmin Within the Dosing Interval | 26.1 ± 13 |
Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.
| mcg/mL | Venetoclax 800 mg |
|---|---|
| Obinutuzumab PK: Cmax | 326 ± 76 |
Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1.
| mcg/mL | Venetoclax PK Popluation |
|---|---|
| Cyclophosphamide PK: Cmax | 32.1 ± 7.51 |
Cmax was determined using the post-dose Doxorubicin plasma concentrations.
| mcg/mL | Venetoclax PK Popluation |
|---|---|
| Doxorubicin PK: Cmax | 1260 ± 911 |
Cmax was determined using the post-dose Vincristine plasma concentrations.
| mcg/mL | Venetoclax PK Popluation |
|---|---|
| Vincristine PK: Cmax | 54.0 ± 44.6 |
Objective Response defined as PR (partial response) or CR (complete response) at end of treatment. CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR
| Percentage of Participants | Venetoclax + R-CHOP 800 mg Phase II |
|---|---|
| Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC | 81.5 (75.61 to 86.51) |
Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: \>/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions.
| Percentage of Participants | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax 800mg + R-CHOP | Venetoclax + R-CHOP 800 mg Phase II | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg + G-CHOP B |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Are Alive and Without Disease Progression at Month 12 | 85.71 (59.79 to 100.00) | 100.00 (100.00 to 100.00) | 87.50 (64.58 to 100.00) | 66.67 (28.95 to 100.00) | 88.99 (82.65 to 92.10) | 100.00 (100.00 to 100.00) | 75.00 (32.57 to 100.00) | 100.00 (100.00 to 100.00) | 100.00 (100.00 to 100.00) | 100.00 (100.00 to 100.00) |
CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to \</= 1.5 cm in longest transverse diameter of a lesion (LDi), no extra-lymphatic sites of disease, absence of non-measured lesions, organ enlargement must have regressed to normal, no new lesions, and if the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
| Percentage of Participants | Venetoclax + R-CHOP 800 mg Phase II |
|---|---|
| Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification | 37.4 (30.89 to 44.35) |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Percentage of Participants | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax 800mg + R-CHOP | Venetoclax + R-CHOP 800 mg Phase II | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg + G-CHOP B |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety: Percentage of Participants With Adverse Events | 100.00 | 100.00 | 100.00 | 100.00 | 99.0 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
Maintenance of relative dose intensity was defined as a dose intensity of \>/= 90%.
| Percentage of participants | Venetoclax + R-CHOP Arm | Venetoclax 600mg + G-CHOP |
|---|---|---|
| Cyclophosphamide | 89.5 | 77.4 |
| Doxorubicin | 88.6 | 77.4 |
| Vincristine | 86.6 | 78.1 |
| Prednisone | 87.4 | 81.3 |
Dose intensity was categorized as \< 80%, 80% to \< 85%, 85% to \< 90%, or \>/= 90%.
| Percentage of Partcipants | Venetoclax 200 mg + R-CHOP | Venetoclax 400 mg + R-CHOP | Venetoclax 600 mg + R-CHOP | Venetoclax 800mg + R-CHOP | Venetoclax + R-CHOP 800 mg Phase II | Venetoclax 200mg + G-CHOP | Venetoclax 400mg + G-CHOP | Venetoclax 600mg + G-CHOP | Venetoclax + G-CHOP 800 mg | Venetoclax + G-CHOP 800mg B |
|---|---|---|---|---|---|---|---|---|---|---|
| <80% | 71.4 | 0.00 | 12.5 | 0.00 | 26.0 | 100.00 | 14.3 | 50.0 | 83.3 | 100.0 |
| 80-<85% | 0.00 | 0.00 | 12.5 | 0.00 | 3.4 | 0.00 | 14.3 | 16.7 | 0.00 | 0.00 |
| 85-<90% | 0.00 | 0.00 | 12.5 | 0.00 | 2.9 | 0.00 | 0.00 | 0.00 | 16.7 | 0.00 |
| >=90% | 28.6 | 100.00 | 62.5 | 100.00 | 67.6 | 0.00 | 71.4 | 33.3 | 0.00 | 0.00 |
Collected over Baseline up to approximately 67 months. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Venetoclax 200 mg +R-CHOP | 1/7 (14.3%) | 5/7 (71.4%) | 7/7 (100%) |
| Venetoclax 400 mg +R-CHOP | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Venetoclax 600 mg +R-CHOP | 1/8 (12.5%) | 4/8 (50%) | 8/8 (100%) |
| Venetoclax 800 mg +R-CHOP | 4/6 (66.7%) | 3/6 (50%) | 6/6 (100%) |
| Venetoclax 800 mg +R-CHOP Phase II | 33/208 (15.9%) | 116/208 (55.8%) | 204/208 (98.1%) |
| Venetoclax 200 mg +G-CHOP | 1/7 (14.3%) | 5/7 (71.4%) | 7/7 (100%) |
| Venetoclax 400 mg +G-CHOP | 1/7 (14.3%) | 4/7 (57.1%) | 7/7 (100%) |
| Venetoclax 600 mg +G-CHOP | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Venetoclax 800 mg + G-CHOP A | 0/6 (0%) | 5/6 (83.3%) | 6/6 (100%) |
| Venetoclax 800 mg +G-CHOP B | 0/6 (0%) | 5/6 (83.3%) | 6/6 (100%) |
| Event | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B |
|---|---|---|---|---|---|---|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 3/7 | 0/3 | 1/8 | 2/6 | 57/208 | 1/7 | 2/7 | 0/6 | 0/6 | 1/6 |
| ANAEMIABlood and lymphatic system disorders | 0/7 | 1/3 | 0/8 | 0/6 | 4/208 | 0/7 | 0/7 | 0/6 | 0/6 | 0/6 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 0/7 | 0/3 | 0/8 | 0/6 | 2/208 | 0/7 | 0/7 | 0/6 | 2/6 | 0/6 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/7 | 1/3 | 0/8 | 0/6 | 6/208 | 0/7 | 0/7 | 0/6 | 0/6 | 0/6 |
| CARDIOMYOPATHYCardiac disorders | 0/7 | 1/3 | 0/8 | 0/6 | 0/208 | 0/7 | 0/7 | 0/6 | 0/6 | 0/6 |
| VOMITINGGastrointestinal disorders | 0/7 | 1/3 | 0/8 | 0/6 | 5/208 | 0/7 | 0/7 | 0/6 | 0/6 | 0/6 |
| NEUTROPENIABlood and lymphatic system disorders | 0/7 | 0/3 | 0/8 | 0/6 | 19/208 | 1/7 | 0/7 | 0/6 | 0/6 | 1/6 |
| CARDIAC ARRESTCardiac disorders | 0/7 | 0/3 | 0/8 | 0/6 | 0/208 | 0/7 | 0/7 | 0/6 | 0/6 | 1/6 |
| TACHYCARDIACardiac disorders | 0/7 | 0/3 | 0/8 | 0/6 | 1/208 | 0/7 | 0/7 | 0/6 | 0/6 | 1/6 |
| DYSPHAGIAGastrointestinal disorders | 0/7 | 0/3 | 0/8 | 0/6 | 0/208 | 0/7 | 0/7 | 1/6 | 0/6 | 0/6 |
| Event | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B |
|---|---|---|---|---|---|---|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 4/7 | 2/3 | 6/8 | 3/6 | 134/208 | 2/7 | 4/7 | 5/6 | 6/6 | 2/6 |
| CONSTIPATIONGastrointestinal disorders | 1/7 | 2/3 | 3/8 | 2/6 | 67/208 | 6/7 | 3/7 | 2/6 | 2/6 | 1/6 |
| ANAEMIABlood and lymphatic system disorders | 4/7 | 0/3 | 1/8 | 2/6 | 73/208 | 1/7 | 1/7 | 1/6 | 5/6 | 4/6 |
| NAUSEAGastrointestinal disorders | 3/7 | 2/3 | 1/8 | 5/6 | 108/208 | 3/7 | 4/7 | 3/6 | 5/6 | 4/6 |
| DIARRHOEAGastrointestinal disorders | 3/7 | 2/3 | 2/8 | 3/6 | 79/208 | 5/7 | 3/7 | 2/6 | 2/6 | 1/6 |
| VOMITINGGastrointestinal disorders | 0/7 | 1/3 | 1/8 | 2/6 | 64/208 | 5/7 | 4/7 | 0/6 | 4/6 | 1/6 |
| FATIGUEGeneral disorders | 5/7 | 0/3 | 3/8 | 2/6 | 81/208 | 5/7 | 2/7 | 2/6 | 3/6 | 1/6 |
| PYREXIAGeneral disorders | 0/7 | 0/3 | 1/8 | 2/6 | 50/208 | 0/7 | 5/7 | 2/6 | 1/6 | 2/6 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 4/7 | 1/3 | 3/8 | 0/6 | 52/208 | 2/7 | 3/7 | 2/6 | 4/6 | 2/6 |
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 1/7 | 2/3 | 1/8 | 2/6 | 44/208 | 4/7 | 1/7 | 2/6 | 2/6 | 3/6 |
| Age, Continuous(Years) | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 67.0 ± 9.2 | 61.0 ± 13.1 | 57.0 ± 9.5 | 56.3 ± 11.9 | 61.4 ± 12.8 | 52.1 ± 16.2 | 60.9 ± 6.3 | 66.7 ± 4.2 | 60.5 ± 13.7 | 66.8 ± 6.7 | 61.2 ± 12.5 |
| Sex: Female, Male(Participants) | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 2 | 2 | 2 | 94 | 2 | 5 | 4 | 4 | 2 | 120 |
| Male | 4 | 1 | 6 | 4 | 114 | 5 | 2 | 2 | 2 | 4 | 144 |
| Ethnicity (NIH/OMB)(Participants) | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 4 |
| Not Hispanic or Latino | 6 | 1 | 2 | 3 | 151 | 6 | 3 | 4 | 5 | 6 | 187 |
| Unknown or Not Reported | 1 | 2 | 6 | 3 | 53 | 1 | 4 | 2 | 1 | 0 | 73 |
| Race (NIH/OMB)(Participants) | Venetoclax 200 mg +R-CHOP | Venetoclax 400 mg +R-CHOP | Venetoclax 600 mg +R-CHOP | Venetoclax 800 mg +R-CHOP | Venetoclax 800 mg +R-CHOP Phase II | Venetoclax 200 mg +G-CHOP | Venetoclax 400 mg +G-CHOP | Venetoclax 600 mg +G-CHOP | Venetoclax 800 mg + G-CHOP A | Venetoclax 800 mg +G-CHOP B | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 3 |
| Black or African American | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 4 |
| White | 6 | 1 | 2 | 2 | 154 | 7 | 2 | 4 | 5 | 4 | 187 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 6 | 4 | 42 | 0 | 4 | 2 | 1 | 2 | 64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in Jun 2017, 43 months.
Results were first posted in Dec 2018, 1 year 5 months after primary completion.
Of 69 industry-sponsored phase 1/2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 103. This study's 43 months is below that.
Counting every sponsor, half of 135 studies reached it within 72 months; a quarter within 50 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Venetoclax · Cyclophosphamide · Obinutuzumab · Rituximab · Doxorubicin · Vincristine · Prednisone